



2024

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Speech Abstract

Topic:

Long-Term Survival Benefits of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: Insights from Real-World Evidence

Abstract

The landscape of HR+/HER2- advanced breast cancer treatment has been significantly transformed by the advent of CDK4/6 inhibitors. While clinical trials have established the efficacy of CDK4/6 inhibitors in improving progression-free survival (PFS), understanding its long-term survival benefits through real-world evidence (RWE) provides a broader perspective on its impact in routine clinical practice.

This presentation aims to elucidate the long-term survival benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer, leveraging insights drawn from real-world data. It will highlight how these benefits compare to those observed in clinical trial settings, focusing on overall survival (OS) and PFS.

Analysis of real-world data indicates that patients treated with CDK4/6 inhibitor, in combination with endocrine therapy, experience significant improvements in both OS and PFS compared to those receiving endocrine therapy alone. The real-world median OS and PFS closely mirror or even surpass those reported in randomized clinical trials, underscoring the robustness of CDK4/6 inhibitor's efficacy.

Integrating real-world evidence into clinical decision-making can enhance treatment strategies, offering a comprehensive understanding of CDK4/6 inhibitor's long-term benefits. Real-world data can help bridge the gap between clinical trial environments and everyday clinical practice, ensuring that treatment benefits are maximized for a broader patient population.

Real-world evidence substantiates the long-term survival benefits of CDK4/6 inhibitor for patients with HR+/HER2- advanced breast cancer, validating its pivotal role in current treatment paradigms. This presentation will provide critical insights into optimizing patient outcomes through the application of real-world data, ensuring that the full potential of CDK4/6 inhibitor is realized in clinical practice.